Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 03, 2022 08:30 ET | Source: Veru Inc.

Veru to Present Corporate Update at the H.C. Wainwright BioConnect Conference on January 10-13, 2022

MIAMI, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer,...
December 13, 2021 08:30 ET | Source: Veru Inc.

Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic Hyperplasia

--ENTADFI (Finasteride and Tadalafil) Capsules to Treat Benign Prostatic Hyperplasia-- --Commercialization Will Start Early Calendar Year 2022-- --ENTADFI to Be Marketed and Distributed by...
December 08, 2021 08:00 ET | Source: Veru Inc.

Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium

MIAMI, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast cancer and prostate...
December 02, 2021 06:30 ET | Source: Veru Inc.

Veru Reports Record Fiscal 2021 Full-Year Financial Results

--FY21 Net Revenues Increase 44% to $61 Million and Gross Profit Increases 56% to $48 Million, Achieving New Historical Highs-- --Phase 3 Sabizabulin COVID-19 Clinical Study for Treatment of...
November 18, 2021 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2021 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 2nd

MIAMI, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer,...
November 18, 2021 08:00 ET | Source: Veru Inc.

Veru Ranked as one of the Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500

-- Veru is a Late-Stage Clinical Development Biopharmaceutical Company Developing Drugs for the Treatment of Breast Cancer, Prostate Cancer, and COVID-19, Large Premium Global Markets– -- 212%...
November 08, 2021 08:30 ET | Source: Veru Inc.

Veru to Participate in Fireside Chat at the Jefferies London Healthcare Conference on November 16-18, 2021

MIAMI, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer,...
October 13, 2021 08:30 ET | Source: Veru Inc.

Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer

-- Enobosarm is a novel targeted hormone drug to be evaluated in the 3rd line treatment of androgen receptor positive metastatic breast cancer -- -- A companion diagnostic test will be developed,...
September 20, 2021 08:30 ET | Source: Veru Inc.

Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress

MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
September 09, 2021 08:30 ET | Source: Veru Inc.

Veru Announces Oral Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress

MIAMI, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...